{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:22:23Z","timestamp":1790022143305,"version":"4.0.1"},"reference-count":12,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It is an unclear how cholesterol\u2010lowering statin drugs affect progression of chronic lymphocytic leukemia (CLL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical records of 57 CLL patients were examined to determine how initiating statins in the \u201cwatch and wait\u201d phase of management affected disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 6.4\u2009\u00b1\u20090.6\u2009months, when average low\u2010density lipoprotein cholesterol levels had been lowered from 3.58\u2009\u00b1\u20090.11\u2009mM to 2.1\u2009\u00b1\u20090.06\u2009mM, blood levels of CLL cells and beta\u20102\u2010microglobulin (\u03b22M) increased significantly, accompanied by significant decreases in platelets. Following statin institution, rates of change of blood lymphocytes and \u03b22M increased from 1.55\u2009\u00b1\u20090.39\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> to 3.4\u2009\u00b1\u20090.68\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells\/mL\/month (<jats:italic>n<\/jats:italic>\u2009=\u200943) and 0.035\u2009\u00b1\u20090.011 to 0.055\u2009\u00b1\u20090.007\u2009\u03bcg\/mL\/month (<jats:italic>n<\/jats:italic>\u2009=\u200940), respectively. Conventional first\u2010line CLL treatment was ultimately required in 37 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These observations suggest that statins as single agent do not slow and may even modestly stimulate progression of CLL.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70881","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:11:23Z","timestamp":1745493083000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Statins in the Watch and Wait Phase of Chronic Lymphocytic Leukemia"],"prefix":"10.1002","volume":"14","author":[{"given":"David E.","family":"Spaner","sequence":"first","affiliation":[{"name":"Biology Platform Sunnybrook Research Institute  Toronto Canada"},{"name":"Department of Immunology University of Toronto  Toronto Canada"},{"name":"Department of Hematology Odette Cancer Center  Toronto Canada"},{"name":"Department of Medical Biophysics University of Toronto  Toronto Canada"},{"name":"Dept. of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V21.6.2024614"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.11.008"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78315-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1088651"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw226"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0212"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.486877"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0597-x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.08.045"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.11.033"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1043694"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:37:05Z","timestamp":1748349425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/cam4.70881"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70881","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70881"}}